viewWillow Biosciences Inc.

ATB Capital says Willow Biosciences faces large commercialization opportunity with initial production run of CBG

Willow has developed a proprietary process to manufacture the cannabis compound in commercial quantities

Willow Biosciences Inc. -
ATB has a Speculative Buy rating on Willow’s shares and a 12-month price target of C$2.75

Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) is poised to be the first company to biosynthetically produce a rare cannabinoid compound known as cannabigerol, or CBG, according to analysts at ATB Capital Markets.

The Canadian biotechnology company announced earlier this week that it is kicking off a 500-litre pilot production run of CBG, a type of cannabinoid with non-psychoactive properties that initial research suggests could have anti-microbial and antioxidant functions.

“We view this announcement as positive as it is another step towards commercializing rare cannabinoids,” analyst David Kideckel wrote in a note this week. “Considering Willow’s large potential addressable market and its steady progress towards commercialization in 2021, we believe the company is trading at an attractive valuation.”

READ: Willow Biosciences kicks off pilot production run of high-purity CBG, a non-psychoactive cannabinoid compound

Willow has developed a proprietary process to manufacture the compound in commercial quantities.

ATB has a Speculative Buy rating on Willow’s shares and a 12-month price target of C$2.75.

Kideckel noted the potential opportunity associated with the commercialization of cannabinoids is “large,” saying that Willow has “come a long way” in improving the visibility over its path to commercialization in 2021.

"We view Willow to be a potential acquisition target for companies looking to develop cannabinoids through biosynthesis, given Willow’s scientific progress to date, its management’s expertise, and its strong intellectual property with multiple patent applications covering more than 200 novel genes to increase cannabinoid production,” Kideckel wrote.

“Most of Willow’s discovered genes are produced by the company’s proprietary genomic databases, which in our view, may lead to multiple additional discoveries and patents in 2020 and beyond, increasing the value of Willow’s intellectual property.”

Willow’s stock was trading 9.4% higher in Toronto on Thursday afternoon at C$0.58.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Willow Biosciences Inc.

Price: 0.58 CAD

Market: TSX
Market Cap: $56.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Willow Biosciences Inc. named herein, including the promotion by the Company of Willow Biosciences Inc. in any Content on the Site, the Company...


Willow Biosciences announces game changing successful production of pure CBG...

Willow Biosciences (TSE: WLLW-OTCQX: CANSF) President and CEO Trevor Peters joined Steve Darling from Proactive with news the company has successfully developed a scalable process for producing cannabigerol with greater than 99% purity and no detectable THC at 500-litre scale. Peters...

on 09/21/2020

2 min read